Zeltia Achieves Consolidated Ebitda Break-Even in 1q10 ; Yondelis(R) Sales Increased by 110% with Respect to 1q09; Biotechnology Net Sales Expanded by 90.9%; Consumer Chemicals Net Sales Increased by 16.5% with Respect to 1q09; Net Income Improved 50% with Respect to 1q09

U.S. Newswire › April 29, 2010

Linked as:

Summary

MADRID, Spain, April 29 /PRNewswire/ -- Consolidated revenues for Zeltia (ZEL.MC) amounted to 32.9 million euro (approximately 163.6 million USD*) in 1Q10, up 49% with respect to 1Q09. Net income improved 50%.

Net revenues in biopharmaceuticals rose 90.9%, primarily due to Yondelis(R) sales, which totaled 16.6 million euro (approximately 22 million USD) in the first quarter. Almost 60 countries worldwide have authorized the sale of Yondelis(R).

See the full content of this document

Extract

Zeltia Achieves Consolidated Ebitda Break-Even in 1q10 ; Yondelis(R) Sales Increased by 110% with Respect to 1q09; Biotechnology Net Sales Expanded by 90.9%; Consumer Chemicals Net Sales Increased by 16.5% with Respect to 1q09; Net Income Improved 50% with Respect to 1q09

Genomica increased total sales by 29.5% to 1.8 million euro (approximately 2.4 million USD).

Consum...

See the full content of this document